Merck & Company, Inc. (MRK) — Stock Price, Financials & Analysis

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Key Statistics — MRK

  • Latest Close: $130.42
  • Market Cap: $321.77B
  • P/E Ratio (TTM): 105.2
  • EPS (TTM): $1.24
  • Dividend Yield: 260.00%
  • Beta: 0.21
  • 52-Week High: $135.05
  • 52-Week Low: $77.58
  • Profit Margin: 4.8%
  • Return on Equity: 7.0%
  • Debt to Equity: 128.4

Sector: Healthcare — Drug Manufacturers - General

Income Statement — MRK

  • 2021: Revenue N/A, Net Income N/A
  • 2022: Revenue $59.28B, Net Income $14.52B
  • 2023: Revenue $60.12B, Net Income $365.0M
  • 2024: Revenue $64.17B, Net Income $17.12B
“”Wednesday, August 12, 2026
Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay§RegretRT=max⁡i∑t=1Tuit−∑t=1TuattR_T = \max_i \sum_{t=1}^{T} u_i^t - \sum_{t=1}^{T} u_{a_t}^tRT​=maxi​∑t=1T​uit​−∑t=1T​uat​t​§LP Dualmin⁡y,ww    s.t.    Ay≤w⋅1\min_{y,w} w \;\; \text{s.t.} \;\; Ay \leq w \cdot \mathbf{1}miny,w​ws.t.Ay≤w⋅1§Payoffu1(i,j)=aij,    u2(i,j)=−aiju_1(i,j) = a_{ij}, \;\; u_2(i,j) = -a_{ij}u1​(i,j)=aij​,u2​(i,j)=−aij​§Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay
0∑×$0 sometimesAlpha v0.1.0

The Shounya

HomeScreenerHeatmapSectorsDividendsCompareWatchlistPortfolioChartTechnicalScannerEarningsCorrelationSector AnalysisInsidersCongressNewsLearnAboutStatus
← Home← ScreenerChart TerminalTechnical
MRKHealthcare

Merck & Company, Inc. — Healthcare · Drug Manufacturers - General

$130.42-0.50 (-0.38%)
Mkt Cap
$321.77B
P/E
105.2
EPS
$1.24
Beta
0.21
Yield
260.00%
52W Hi
$135.05
52W Lo
$77.58
Vol
10.2M

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
73,000
HQ
Rahway, NJ, United States
Web
merck.com

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Top Executives

NameTitleTotal Pay
Mr. Robert M. Davis J.D.Chairman, President & CEO$4.6M
Ms. Caroline A. LitchfieldExecutive VP & CFO$2.4M
Ms. Jennifer L. Zachary J.D.Executive VP & General Counsel$2.2M
Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories$3.0M
Mr. Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller—
Mr. David Michael WilliamsExecutive VP and Chief Information & Digital Officer—
Mr. Peter DannenbaumVice President of Investor Relations—
Mr. Chirfi GuindoExecutive Vice President of Strategic Access, Policy & Communications$1.5M
Ms. Betty D. LarsonExecutive VP & Chief Human Resources Officer$2.3M
Mr. Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health$2.2M

Financial Statements

✓
Profitable
4/5 periods
✓
Revenue Growing
+1.3% latest, 3/3 up
✓
Earnings Growing
+6.6% latest, 2/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
4.8% net margin

Merck & Company, Inc.

Healthcare \u00b7 Drug Manufacturers - General

Market Cap$321.77B
Trailing P/E105.2
Forward P/E13.7
EPS (trailing)$1.24
EPS (forward)$9.55
Gross Margin75.9%
Operating Margin-0.2%
Profit Margin4.8%
Dividend Rate$3.40/share
Dividend Yield260.0%
Payout Ratio268.8%

Revenue & Net Income

2021 – 2025, Annual

Revenue

Net Income

Profit Margins

2021 – 2025, Annual

Earnings Per Share

2021 – 2025, Annual

Dividends

No dividend history available.

Price Ranges

52-Week
$77.58$135.05
Fwd P/E13.7
Avg Volume10.2M
Shares Out2.47B

Key Ratios

Gross Margin75.9%
Operating Margin-0.2%
Profit Margin4.8%
ROE7.0%
ROA11.9%
P/B7.7
D/E128.41
Current Ratio1.32
Dividend Rate$3.40
Payout Ratio268.8%

Cash & Debt

Cash 12%Debt 88%
Total Cash$7.14B
Total Debt$53.91B
Net Cash$-46.77B
Free Cash Flow$15.17B
Operating CF$19.97B

Ratings Snapshot

2.2 / 5
P/E1/5(105.2)
P/B2/5(7.7)
ROE2/5(7.0)
ROA4/5(11.9)
D/E1/5(128.4)
Liquidity3/5(1.3)

Growth Pulse

Revenue Growth+5.1%

Analyst Recommendations

0m
Buy (28 analysts)
4
15
8
Strong Buy: 4
Buy: 15
Hold: 8
Sell: 0
Strong Sell: 1
MonthStr BuyBuyHoldSellStr Sell
0m415801
-1m415801
-2m415901
-3m4151000

Income Snapshot 2025

Revenue
$65.0B
Net Income
$18.3B
Gross Margin
74.8%
Net Margin
28.1%
Op. Income
$22.1B
EPS
$7.38

Balance Sheet

2021 – 2025, Annual
Debt / Equity0.94x
Owns more than it owes — healthy
Current Ratio1.54x
Can easily cover short-term bills
Net Debt$34.77B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$109.16B$63.10B$45.99B$12.69B$30.69B0.67x
2023$106.67B$69.04B$37.58B$6.84B$35.05B0.93x
2024$117.11B$70.73B$46.31B$13.24B$37.11B0.80x
2025$136.87B$84.20B$52.61B$14.56B$49.34B0.94x

Balance Sheet Snapshot 2025

Total Assets$136.87B
Total Liabilities$84.20B
Equity$52.61B
Retained Earnings$73.08B
Goodwill$21.58B
Long-Term Debt$46.75B

Cash Flow Statement

2021 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2021$0$0$0$0$0
2022$19B$-5B$-9B$15B$-4B
2023$13B$-14B$-5B$9B$-4B
2024$21B$-8B$-7B$18B$-3B
2025$16B$-14B$-2B$12B$-4B

Capital Allocation 2025

CapEx$4.11B
Dividends Paid$8.18B
Buybacks$5.08B
Debt Repaid$2.50B
Debt Issued$13.88B
Net Change Cash$809.0M

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
73,000
HQ
Rahway, NJ, United States
Web
merck.com

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Top Executives

NameTitleTotal Pay
Mr. Robert M. Davis J.D.Chairman, President & CEO$4.6M
Ms. Caroline A. LitchfieldExecutive VP & CFO$2.4M
Ms. Jennifer L. Zachary J.D.Executive VP & General Counsel$2.2M
Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories$3.0M
Mr. Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller—
Mr. David Michael WilliamsExecutive VP and Chief Information & Digital Officer—
Mr. Peter DannenbaumVice President of Investor Relations—
Mr. Chirfi GuindoExecutive Vice President of Strategic Access, Policy & Communications$1.5M
Ms. Betty D. LarsonExecutive VP & Chief Human Resources Officer$2.3M
Mr. Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health$2.2M

Price Ranges

52-Week
$77.58$135.05
Fwd P/E13.7
Avg Volume10.2M
Shares Out2.47B

Key Ratios

Gross Margin75.9%
Operating Margin-0.2%
Profit Margin4.8%
ROE7.0%
ROA11.9%
P/B7.7
D/E128.41
Current Ratio1.32
Dividend Rate$3.40
Payout Ratio268.8%

Cash & Debt

Cash 12%Debt 88%
Total Cash$7.14B
Total Debt$53.91B
Net Cash$-46.77B
Free Cash Flow$15.17B
Operating CF$19.97B

Ratings Snapshot

2.2 / 5
P/E1/5(105.2)
P/B2/5(7.7)
ROE2/5(7.0)
ROA4/5(11.9)
D/E1/5(128.4)
Liquidity3/5(1.3)

Growth Pulse

Revenue Growth+5.1%

Analyst Recommendations

0m
Buy (28 analysts)
4
15
8
Strong Buy: 4
Buy: 15
Hold: 8
Sell: 0
Strong Sell: 1
MonthStr BuyBuyHoldSellStr Sell
0m415801
-1m415801
-2m415901
-3m4151000

Financial Statements

✓
Profitable
4/5 periods
✓
Revenue Growing
+1.3% latest, 3/3 up
✓
Earnings Growing
+6.6% latest, 2/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
4.8% net margin

Merck & Company, Inc.

Healthcare \u00b7 Drug Manufacturers - General

Market Cap$321.77B
Trailing P/E105.2
Forward P/E13.7
EPS (trailing)$1.24
EPS (forward)$9.55
Gross Margin75.9%
Operating Margin-0.2%
Profit Margin4.8%
Dividend Rate$3.40/share
Dividend Yield260.0%
Payout Ratio268.8%

Revenue & Net Income

2021 – 2025, Annual

Revenue

Net Income

Profit Margins

2021 – 2025, Annual

Earnings Per Share

2021 – 2025, Annual

Dividends

No dividend history available.

Income Snapshot 2025

Revenue
$65.0B
Net Income
$18.3B
Gross Margin
74.8%
Net Margin
28.1%
Op. Income
$22.1B
EPS
$7.38

Balance Sheet

2021 – 2025, Annual
Debt / Equity0.94x
Owns more than it owes — healthy
Current Ratio1.54x
Can easily cover short-term bills
Net Debt$34.77B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$109.16B$63.10B$45.99B$12.69B$30.69B0.67x
2023$106.67B$69.04B$37.58B$6.84B$35.05B0.93x
2024$117.11B$70.73B$46.31B$13.24B$37.11B0.80x
2025$136.87B$84.20B$52.61B$14.56B$49.34B0.94x

Balance Sheet Snapshot 2025

Total Assets$136.87B
Total Liabilities$84.20B
Equity$52.61B
Retained Earnings$73.08B
Goodwill$21.58B
Long-Term Debt$46.75B

Cash Flow Statement

2021 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2021$0$0$0$0$0
2022$19B$-5B$-9B$15B$-4B
2023$13B$-14B$-5B$9B$-4B
2024$21B$-8B$-7B$18B$-3B
2025$16B$-14B$-2B$12B$-4B

Capital Allocation 2025

CapEx$4.11B
Dividends Paid$8.18B
Buybacks$5.08B
Debt Repaid$2.50B
Debt Issued$13.88B
Net Change Cash$809.0M
0∑×

Free market data & analysis tools.

Markets
HomeScreenerHeatmapSectorsEarnings
Tools
WatchlistCompareChart TerminalTechnical
Research
CongressInsidersDividendsCorrelation
© 2026 ShounyaAlpha v0.1.0Not financial advice · hanabira.org